Interns Help Facilitate Breast Cancer Conversations Among Young Black Women
Four Questions with Tracey Iraca: Combating Age-Related Disparities in Blood Cancer Treatment
As a former collegiate women’s basketball coach, Stephanie Glance has observed her share of tough battles on the court. But none were as fierce as what she saw her mentor and friend, Coach Kay Yow, go through while living with breast cancer for 22 years.
As a physician treating children living with HIV at an infectious disease hospital in Shanxi, China, Guo Xiaoping hatched an ambitious plan. His goals? To create a place for the students to learn and live and to help reduce the intense stigma they often face from external communities.
Over the past 18 months, the COVID-19 pandemic has brought the treatment and prevention of infectious diseases to center stage. For Dr. Adeeba Kamarulzaman, Dean of the Faculty of Medicine at University of Malaya in Kuala Lumpur, Malaysia, and Dr. Sharon Lewin, Professor of Medicine at the University of Melbourne in Melbourne, Australia, the pandemic offers an opportunity for the global health community to review its approach to HIV prevention and treatment and to plot a stronger course going forward.
When Wayne Duffus moved from Jamaica to New York after high school, he quickly developed an interest in science thanks to a handful of inspiring mentors. His family was immigrating to the United States, and he was excited to attend City University of New York – Brooklyn College. After graduation, as he continued exploring his newly found passion, he enrolled in an MD-PhD program at the Albert Einstein College of Medicine and eventually went on to specialize in infectious diseases to help fight the growing HIV epidemic. Since then, he has focused his work on HIV prevention in the clinical, public health and government sectors.
At Gilead, we are dedicated to looking beyond the obvious to solve complex problems. Read more about our efforts to rise beyond in 2020 as we worked amid the pandemic to deliver for patients.
Gilead Sciences to Acquire Immunomedics
An Open Letter from Daniel O'Day, Chairman & CEO, Gilead Sciences